View Post

Startup joins Roche to hold clinical trials for double-whammy cancer drug

In Clinical Trials by Barbara Jacoby

By: Shoshanna Solomon From: imesofisrael.com DSP-107, developed by KAHR Medical, hopes to have dual impact: tag cancer cells, and boost activity of the immune cells that target them KAHR Medical, an Israeli biopharmaceutical company, says it is developing a second generation class of  immunotherapy drugs that it hopes will be more effective in tackling cancer, based on the lessons learned …

View Post

Roche drug is third to win biomarker-driven cancer approval from FDA

In Clinical Trials by Barbara Jacoby

By: Alaric DeArment From: medcitynews.com Another drug designed to treat cancer patients based on a genetic driver rather than where tumors occur in the body has received approval from the Food and Drug Administration. The FDA on Thursday granted Swiss drugmaker Roche’s Rozlytrek (entrectinib) approval for ROS1-positive non-small cell lung cancer and accelerated approval for solid tumors with NTRK gene …

View Post

New Companion Diagnostic Test Launched for Patients With Breast, Gastric Cancers

In In The News by Barbara Jacoby

By: Gina Columbus From: targetedonc.com A new VENTANA HER2 dual in situ hybridization (ISH) companion diagnostic assay has been launched by Roche to help identify HER2 amplification for patients with breast cancer and gastric cancer who could be eligible to receive trastuzumab (Herceptin). The VENTANA HER2 Dual ISH DNA Probe Cocktail assay is designed to identify patients who have HER2-positive breast or gastric …

View Post

Roche’s ipatasertib combo shows early promise in triple-negative breast cancer

In Clinical Trials by Barbara Jacoby

By: Anna Smith From: pharmatimes.com Roche has announced results from a Phase Ib trial assessing its AKT-inhibitor ipatasertib, Tecentriq (atezolizumab) and chemotherapy in triple-negative breast cancer (TNBC), showing a 73% overall response rate irrespective of PD-L1 status. Out of the first 26 subjects in the study, 19 had confirmed responses.The trial consisted of two arms; ipatasertib in combination with Tecentriq and …

View Post

Immatics Announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers

In Clinical Trials by Barbara Jacoby

Source: Immatics From: pipelinereview.com Immatics today announced a collaboration with Roche to evaluate the safety and efficacy of IMA101, Immatics’ investigational autologous cell therapy, in combination with atezolizumab (TECENTRIQ®), in patients with solid cancers. IMA101 is a personalized, multi-targeted investigational immunotherapy for the treatment of multiple advanced / metastatic solid tumors. IMA101 is based on Immatics’ ACTolog® approach, which follows …

View Post

Roche says new drug shows benefits in lung, bladder cancer tests

In In The News by Barbara Jacoby

By: John Miller From: reuters.com Roche ‘s new immune-system boosting cancer drug has given positive results in tests on patients suffering from some lung and bladder cancers, according to data released on Sunday at the European Cancer Congress in Vienna that the company hopes will help it win quick regulatory approval. In its Phase II trial targeting advanced or metastatic …

View Post

Roche’s Atezolizumab Could Spur Long-awaited Bladder Cancer Treatment Innovation, says GlobalData Analyst

In In The News by Barbara Jacoby

Atezolizumab poised to become a major bladder cancer therapy in the race for FDA approval, following positive Phase II trial results The drug will face strong competition in the bladder cancer treatment arena, especially from Bristol-Myers Squibb’s Opdivo and Merck & Co.’s Keytruda, says analyst Roche’s atezolizumab is poised to become a major bladder cancer therapy in the race for …

View Post

EU Recommends Approval of Roche’s Pre-Surgery Breast Cancer Treatment

In In The News, Uncategorized by Barbara Jacoby

From: dddmag.com Roche announced that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approves the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for the neoadjuvant treatment (use before surgery) of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. The EU filing was …

View Post

Double blow for Roche as breast cancer, Alzheimer’s studies fail

In In The News by Barbara Jacoby

By: Silke Koltrowitz and Ben Hirschler From: yahoo.com Roche suffered a double blow on Friday as two clinical studies of drugs for breast cancer and Alzheimer’s disease failed, sparking the biggest percentage fall in its stock in five years. The Swiss drugmaker said it was ending a late-stage study of experimental Alzheimer’s drug gantenerumab after it failed to prove effective, …

View Post

Bladder Cancer Breakthrough Treatment Developed after 30 Years

In In The News by Barbara Jacoby

A much-awaited breakthrough in the treatment for advanced bladder cancer has been made by scientists from the Barts Cancer Institute of Queen Mary University of London. The breakthrough, which is the first major advancement in the treatment of the dreaded disease over the past 30 years, is detailed in a paper published in the Nature journal. The research studied MPDL3280A, an …